IDEAYA Biosciences, Inc.
3.76xPrice / book
Market cap
$3.85B
Tangible equity
—
Price / tangible book
—
Price / book
3.76x
Return on equity
-11.1%
Return on assets
-10.2%
Efficiency ratio
—
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: IDYA stock price at premium vs MTB $39.88 current versus $12.59 implied using P/B multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MTB's multiple
Implied fair value · at IDYA's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Filter, sort, and scan the equity metrics that matter most for banks: book value, tangible book, returns, and operating efficiency.
Multiple premium
Lower is better
Profitability lag
Asset efficiency lag
Lower is better
Statements
Bank-focused income statement and equity metrics aligned to the reporting windows.
SEC periods: IDYA FY 2025 (ended Dec 31, 2025) · MTB FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Tangible book and profitability anchor a bank, not enterprise value.
Deposits and cash-like balances distort enterprise value for banks, so this section reads equity value, tangible book and profitability instead.
Price / book
Market cap
$3.85B
Tangible equity
—
Price / tangible book
—
Price / book
3.76x
Return on equity
-11.1%
Return on assets
-10.2%
Efficiency ratio
—
Price / tangible book
Market cap
$34.64B
Tangible equity
$20.65B
Price / tangible book
1.68x
Price / book
1.19x
Return on equity
9.8%
Return on assets
1.3%
Efficiency ratio
41.5%
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
IDEAYA Biosciences, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
M&T BANK CORPORATION · implied price per share
Bank model off — standard DCF modelling is disabled for financial institutions.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.08x
0.45x
Net debt / EBITDA
Leverage against operating earnings
4.97x
—
Cash and equivalents
Liquid reserves on the balance sheet
$639.39M
—
Total debt
Interest-bearing obligations outstanding
$84.13M
$13.06B
Comparable set
Where the pair sits against the wider banking comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Zentalis Pharmaceuticals, Inc.
IDYA vs ZNTL
Blueprint Medicines Corp
IDYA vs BPMC
Jazz Pharmaceuticals plc
IDYA vs JAZZ
Sarepta Therapeutics, Inc.
IDYA vs SRPT
JPMorgan Chase & Co.
IDYA vs JPM
Bank of America Corporation
IDYA vs BAC
Wells Fargo & Company
IDYA vs WFC
Citigroup Inc.
IDYA vs C
PNC FINANCIAL SERVICES GROUP, INC.
IDYA vs PNC
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.